Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock

Critical Care Medicine

Volumn 35, Issue 10, 2007, Pages 2280-2285

  Luckner, Günter ^a   Mayr, Viktoria D ^a   Jochberger, Stefan ^a   Wenzel, Volker ^a   Ulmer, Hanno ^b   Hasibeder, Walter R ^c   Dünser, Martin W ^d  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Krankenhaus der Barmherzigen Schwestern Ried Betriebsgesellschaft mbH   (Austria)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

Dosage; Norepinephrine; Treatment efficacy; Vasodilatory shock; Vasopressin

Indexed keywords

ADRENALIN; ARGIPRESSIN; BASE; BILIRUBIN; LACTIC ACID; LIVER ENZYME; MILRINONE; NORADRENALIN;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL BLOOD; ARTICLE; BILIRUBIN BLOOD LEVEL; CENTRAL VENOUS PRESSURE; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG RESPONSE; FEMALE; HEART FAILURE; HEART INDEX; HEMODYNAMICS; HUMAN; LABORATORY TEST; LACTATE BLOOD LEVEL; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; PH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHOCK; SIDE EFFECT; STATISTICAL ANALYSIS; THROMBOCYTE COUNT; VASODILATORY SHOCK;

AGED; ARGININE VASOPRESSIN; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; SHOCK; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 34748842058     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CCM.0000281853.50661.23     Document Type: Article

References (25)

1. Dellinger PR, Carlet JM, Masur H, et al: Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004; 32:858-873
2. Mutlu GM, Factor P: Role of vasopressin in the management of septic shock. Intensive Care Med 2004; 30:1276-1291
3. Russell JA, Cooper DJ, Walley KR, et al: Vasopressin and Septic Shock Trial (VASST): Baseline characteristics and organ dysfunction in vasopressor dependent patients with septic shock. Am J Respir Crit Care Med 2003; 167:A548
4. Holmes CL, Walley KR, Chittock DR, et al: The effects of vasopressin on hemodynamics and renal function in severe septic shock: A case series. Intensive Care Med 2001; 27:1416-1421
5. Klinzing S, Simon M, Reinhart K, et al: High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31:2646-2650
6. Luckner G, Dünser MW, Jochberger S, et al: Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005; 33:2659-2666
7. Dünser MW, Mayr AJ, Hanno U, et al: Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003; 107:2313-2319
8. Landry DW, Levin HR, Gallant EM, et al: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95:1122-1125
9. Patel BM, Chittock DR, Russell JA, et al: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96:576-582
10. Dünser MW, Mayr AJ, Tür A, et al: Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: Incidence and risk factors. Crit Care Med 2003; 31:1394-1398
11. Landry DW, Oliver JA: The pathogenesis of vasodilatory shock. N Engl J Med 2001; 345:588-595
12. Goris RJA, te Boekhorst TPA, Nuytinck JKS, et al: Multiple-organ failure. Arch Surg 1985; 120:1109-1115
13. Laird NM, Ware JH: Random effects models for longitudinal data. Biometrics 1982; 38:963-974
14. Westphal M, Stubbe H, Sielenkämper AW, et al: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 2003; 31:1502-1508
15. Roth BL, Spitzer JA: Altered hepatic vasopressin and alpha 1-adrenergic receptors after chronic endotoxin infusion. Am J Physiol 1987; 252:699-702
16. Hollenberg SM, Tangora JJ, Piotrowski MJ, et al: Impaired microvascular vasoconstrictive responses to vasopressin in septic rats. Crit Care Med 1997; 25:869-873
17. Malay MB, Ashton RC Jr, Landry DW, et al: Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999; 47:699-703
18. Tsuneyoshi I, Yamada H, Kakihana Y, et al: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001; 29:487-493
19. Bayram M, De Luca L, Massie MB, et al: Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005; 96:47-58
20. Russell JA: The VASST (vasopressin vs. norepinephrine in septic shock study). Oral presentation, European Society of Intensive Care Medicine, 19th Annual Congress Barcelona, Spain, September 27, 2006. Available at: http://www.esicm.org/Data/ModuleGestionDeContenu/PagesGenerees/07-congresses/ 0A-annual-congress/105.asp#
21. Henrion J, Schapira M, Luwaert R, et al: Hypoxic hepatitis: Clinical and hemodynamic study in 142 consecutive cases. Medicine 2003; 82:392-406
22. Filep J, Rosenkranz B: Mechanisms of vasopressin-induced platelet aggregation. Thromb Res 1987; 45:7-15
23. Dünser MW, Fries DR, Schobersberger W, et al: Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome? Anesth Analg 2004; 99:201-206
24. Hamada Y, Karjalainen A, Setchell BA, et al: Concomitant stimulation by vasopressin of biliary and perfusate calcium fluxes in the perfused rat liver. Biochem J 1992; 281:387-392
25. Ballatori N, Truong AT: Cholestasis, altered junctional permeability, and inverse changes in sinusoidal and biliary glutathione release by vasopressin and epinephrine. Mol Pharmacol 1990; 38:64-71